Literature DB >> 11500420

DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene.

A E Fujimura1, S S Kinoshita, V L Pereira-Chioccola, M M Rodrigues.   

Abstract

Immunization of BALB/c mice with a plasmid containing the gene for Trypanosoma cruzi trans-sialidase (TS) induced antibodies that inhibited TS enzymatic activity, CD4+ Th1 and CD8+ Tc1 cells, and protective immunity against infection. We used this model to obtain basic information on the requirement of CD4 or CD8 or B-cell epitopes for an effective DNA-induced immunity against T. cruzi infection. For that purpose, mice were immunized with plasmids containing DNA sequences encoding (i) the entire TS protein, (ii) the TS enzymatic domain, (iii) the TS CD4+ T-cell epitopes, (iv) the TS CD8+ T-cell epitope, or (v) TS CD4+ and CD8+ T-cell epitopes. Plasmids expressing the entire TS or its enzymatic domain elicited similar levels of TS-inhibitory antibodies, gamma interferon (IFN-gamma)-producing T cells, and protective immunity against infection. Although the plasmid expressing TS CD4 epitopes was immunogenic, its protective efficacy against experimental infection was limited. The plasmid expressing the CD8 epitope was poorly immunogenic and provided little protective immunity. The reason for the limited priming of CD8+ T cells was due to a requirement for CD4+ T cells. To circumvent this problem, a plasmid expressing both CD4+ and CD8+ T-cell epitopes was produced. This plasmid generated levels of IFN-gamma-producing T cells and protective immunity comparable to that of the plasmid expressing the entire catalytic domain of TS. Our observations suggest that plasmids expressing epitopes recognized by CD4+ and CD8+ T cells may have a better protective potential against infection with T. cruzi.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11500420      PMCID: PMC98660          DOI: 10.1128/IAI.69.9.5477-5486.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

1.  Quantitative and qualitative analyses of the immune responses induced by a multivalent minigene DNA vaccine.

Authors:  L L An; F Rodriguez; S Harkins; J Zhang; J L Whitton
Journal:  Vaccine       Date:  2000-04-14       Impact factor: 3.641

2.  Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection.

Authors:  B Wizel; N Garg; R L Tarleton
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

3.  Induction of cytotoxic T-cell responses by gene gun DNA vaccination with minigenes encoding influenza A virus HA and NP CTL-epitopes.

Authors:  A Fomsgaard; H V Nielsen; N Kirkby; K Bryder; S Corbet; C Nielsen; J Hinkula; S Buus
Journal:  Vaccine       Date:  1999-11-12       Impact factor: 3.641

4.  Trypanosoma cruzi infection in MHC-deficient mice: further evidence for the role of both class I- and class II-restricted T cells in immune resistance and disease.

Authors:  R L Tarleton; M J Grusby; M Postan; L H Glimcher
Journal:  Int Immunol       Date:  1996-01       Impact factor: 4.823

5.  Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene.

Authors:  M M Rodrigues; M Ribeirão; V Pereira-Chioccola; L Renia; F Costa
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

6.  Optimization of codon usage of plasmid DNA vaccine is required for the effective MHC class I-restricted T cell responses against an intracellular bacterium.

Authors:  M Uchijima; A Yoshida; T Nagata; Y Koide
Journal:  J Immunol       Date:  1998-11-15       Impact factor: 5.422

7.  Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria.

Authors:  S Li; M Rodrigues; D Rodriguez; J R Rodriguez; M Esteban; P Palese; R S Nussenzweig; F Zavala
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

8.  Mediation of Trypanosoma cruzi invasion by sialic acid on the host cell and trans-sialidase on the trypanosome.

Authors:  M Ming; M Chuenkova; E Ortega-Barria; M E Pereira
Journal:  Mol Biochem Parasitol       Date:  1993-06       Impact factor: 1.759

Review 9.  Structural and functional properties of Trypanosoma trans-sialidase.

Authors:  S Schenkman; D Eichinger; M E Pereira; V Nussenzweig
Journal:  Annu Rev Microbiol       Date:  1994       Impact factor: 15.500

10.  Trypanosoma cruzi trans-sialidase: enhancement of virulence in a murine model of Chagas' disease.

Authors:  M Chuenkova; M E Pereira
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

View more
  27 in total

1.  CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2.

Authors:  Adriano F S Araújo; Bruna C G de Alencar; José Ronnie C Vasconcelos; Meire I Hiyane; Cláudio R F Marinho; Marcus L O Penido; Silvia B Boscardin; Daniel F Hoft; Ricardo T Gazzinelli; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Long-Term Immunity to Trypanosoma cruzi in the Absence of Immunodominant trans-Sialidase-Specific CD8+ T Cells.

Authors:  Charles S Rosenberg; Weibo Zhang; Juan M Bustamante; Rick L Tarleton
Journal:  Infect Immun       Date:  2016-08-19       Impact factor: 3.441

3.  Type 1 immunity provides both optimal mucosal and systemic protection against a mucosally invasive, intracellular pathogen.

Authors:  Daniel F Hoft; Chris S Eickhoff
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

4.  An immunoinformatic approach for identification of Trypanosoma cruzi HLA-A2-restricted CD8(+) T cell epitopes.

Authors:  Christopher S Eickhoff; Daniel Van Aartsen; Frances E Terry; Sheba K Meymandi; Mahmoud M Traina; Salvador Hernandez; William D Martin; Leonard Moise; Annie S De Groot; Daniel F Hoft
Journal:  Hum Vaccin Immunother       Date:  2015-06-24       Impact factor: 3.452

5.  Immunization with cDNA expressed by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infection.

Authors:  Silvia B Boscardin; Sheila S Kinoshita; Adriana E Fujimura; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

6.  Immune responses to gp82 provide protection against mucosal Trypanosoma cruzi infection.

Authors:  Christopher S Eickhoff; Olivia K Giddings; Nobuko Yoshida; Daniel F Hoft
Journal:  Mem Inst Oswaldo Cruz       Date:  2010-08       Impact factor: 2.743

7.  Anatomical route of invasion and protective mucosal immunity in Trypanosoma cruzi conjunctival infection.

Authors:  O K Giddings; C S Eickhoff; T J Smith; L A Bryant; D F Hoft
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

8.  Recombinant Mycobacterium bovis BCG is a promising platform to develop vaccines against Trypansoma cruzi infection.

Authors:  I Bontempi; K Leal; E Prochetto; G Díaz; G Cabrera; A Bortolotti; H R Morbidoni; S Borsuk; O Dellagostin; I Marcipar
Journal:  Clin Exp Immunol       Date:  2020-07-06       Impact factor: 4.330

9.  Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection.

Authors:  Nisha Garg; Rick L Tarleton
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

10.  Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease.

Authors:  Eduardo L V Silveira; Carla Claser; Filipe A B Haolla; Luiz G Zanella; Mauricio M Rodrigues
Journal:  Clin Vaccine Immunol       Date:  2008-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.